Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

LATEST DEVELOPMENTS IN RESPECT OF THE DISCLOSEABLE TRANSACTION PROPOSED PUBLIC TENDER OFFER FOR SHARES IN A VIETNAMESE COMPANY

Reference is made to the announcement of Livzon Pharmaceutical Group Inc.*(麗珠醫藥集團股份有限公司) (the "**Company**") dated 22 May 2025 (the "**Initial Acquisition Announcement**"), the announcement dated 30 December 2025 (the "**Tender Offer Announcement**") and the announcement dated 6 March 2026 (together with the Initial Acquisition Announcement and the Tender Offer Announcement, the "**Announcements**") in relation to the proposed acquisition and proposed voluntary public tender offer for the equity interests in Imexpharm Corporation ("**IMP**"), a listed company in Vietnam. Unless the context otherwise requires, the terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company held the 25th meeting of the 11th Board of Directors on 22 May 2025 and the 31st meeting of the 11th Board of Directors on 30 December 2025 (collectively, the "**Relevant Board Meetings**"), at which the Board approved the Proposal on the Proposed Acquisition of Equity Interests in Vietnam IMP Corporation and the Proposal on the Proposed Voluntary Public Tender Offer for Equity Interests in Vietnam IMP Corporation, and resolved to approve LIAN SGP HOLDING PTE. LTD. ("**LIAN SGP**") to submit an application to the State Securities Commission of Vietnam (the "**SSCV**") for the voluntary public tender offer for the shares in IMP in accordance with the relevant provisions of Vietnam, and to make a voluntary public tender offer to all shareholders of IMP.

The upper limit of the number of shares under the aforesaid tender offer is 120,059,970 shares, representing 77.94% of the registered capital of IMP and 77.96% of the voting shares of IMP. The public tender offer price is VND57,400 per share (equivalent to approximately RMB15.37 based on the central parity rate of exchange on the date of approval at the 31st meeting of the 11th Board of Directors).

As at the date of this announcement, the public tender offer period has ended and LIAN SGP will hold 104,545,781 shares of the target company, representing 67.87% of the registered capital of IMP, and also representing 67.88% of the voting shares of IMP. The public tender offer price is VND57,400 per share, and the total share acquisition consideration payable by LIAN SGP is VND6,000,927,829,400 (equivalent to approximately RMB1.562 billion based on the central parity rate of exchange on the date of the acquisition result report).

Upon expiry of the public tender offer period, LIAN SGP will proceed with the payment of the share acquisition consideration and the share delivery procedures accordingly.

The contemplated transaction is subject to uncertainties due to factors including but not limited to market changes, the subsequent implementation of the transaction and the approval procedures required by all relevant parties. The Company will, in accordance with the progress of the contemplated transaction, strictly comply with the provisions of the Company Law of the People's Republic of China, the Listing Rules of the Shenzhen Stock Exchange,the Self-Regulatory Guidelines for Listed Companies on the Main Board of the Shenzhen Stock Exchange No. 1 - Compliance Operations of Main Board Listed Companies, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**") and other applicable laws, regulations, normative documents as well as the Articles of Association of Livzon Pharmaceutical Group Inc., to perform the necessary review procedures and information disclosure obligations. Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Liu Ning
Company Secretary

Zhuhai, China
29 April 2026

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (Vice Chairman); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

** For identification purpose only*